Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study.

Giuseppe ProcopioVincenzo Emanuele ChiuriMonica GiordanoGiovanna MantiniRoberto MaisanoRoberto BordonaroNicola CalvaniGaetano FacchiniSabino De PlacidoMario AiroldiAndrea SbranaDonatello GasparroGiuseppe Mario LudovicoPamela GuglielminiEmanuele NaglieriDaniele FagnaniMassimo AgliettaLuigi SchipsPatrizia BeccagliaAlessandro SciarraLorenzo LiviDaniele Santini

Published in: Therapeutic advances in medical oncology (2020)

Abiraterone plus prednisone is effective and safe for chemotherapy-naïve mCRPC patients in clinical practice.

Keyphrases

end stage renal disease
clinical practice
chronic kidney disease
newly diagnosed
ejection fraction
randomized controlled trial
locally advanced
systematic review
peritoneal dialysis
prognostic factors
squamous cell carcinoma
rectal cancer